ATX — Amplia Therapeutics Share News
0.000.00%
- AU$40.53m
- AU$13.02m
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement
Brief: Amplia Therapeutics Announces Appointment Of Hamish George As CFO
Brief: Amplia Therapeutics Announces Opening Of Us Sites For Amplicity Pancreatic Cancer Trial
Brief: Amplia Enters Into Second Agreement With Korean Drug Screening Company Next&Bio
Brief: Amplia Therapeutics Key Narmafotinib Patent Granted In U.S.
Australia's Amplia Therapeutics falls as HY loss widens
Brief: Amplia Therapeutics Posts HY Loss Attributable A$4.1 Million
Brief: Amplia Therapeutics Announces A$25M Placement And Launches A$2.5M SPP
Australia's Amplia Therapeutics slips on discounted capital raise
Brief: Amplia Therapeutics Seeks Trading Halt Pending Announcement On Capital Raising
Brief: Amplia Therapeutics Receives US Ethics Clearance For Pancreatic Cancer Trial
Australia's Amplia Therapeutics jumps on upbeat trial results for pancreatic cancer drug
Brief: Amplia Therapeutics To Raise Up To A$13M
Brief: Amplia Therapeutics Seeks Trading Halt
Brief: Amplia Therapeutics Says FDA Fast Track Designation For Narmafotinib In Advanced Pancreatic Cancer
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug